

# Antiretroviral Drugs Treatment for Prevention of HIV

Prema Menezes\*

Department of Medicine, University of North Carolina at Chapel Hill, USA

## Description

The treatment of HIV/AIDS with prescriptions is called antiretroviral treatment (ART). It is suggested for each and every individual who has HIV. The drugs don't fix HIV contamination, yet they really do make it a reasonable persistent condition. They likewise diminish the danger of spreading the infection to other people. When and how you take your ART will vary depending on the specific antiretroviral drugs you take. Most antiretroviral drugs are taken once a day, with or without food. However, some drugs are taken twice a day. If this might be something you find difficult, talk to your doctor about your options.

When you start ART you should accept it appropriately and don't miss or skip dosages, as this can prompt something many refer to as HIV drug opposition, and may imply that your medications don't fill in too for you later on. Assuming that you're thinking that it is difficult to take your treatment at the perfect opportunities and in the correct manner, address your medical services specialist. They can offer you backing and offer you guidance on the most proficient method to make taking your treatment more straight forward. HIV prescriptions can assist with bringing down your viral burden, battle diseases, and work on your personal satisfaction. They can bring down your possibilities communicating HIV, however assuming you take them inaccurately, you can in any case give HIV to other people. They're not a remedy for HIV.

The FDA has endorsed multiple dozen antiretroviral medications to treat HIV contamination. They're frequently broken into six gatherings since they work in various ways. Specialists suggest taking a mix or "mixed drink" of something like two of them. This is called antiretroviral treatment, or ART. Your primary care physician will tell you explicitly the way that you should accept your prescriptions. You really want to follow the bearings precisely, and you shouldn't miss even one portion. Assuming you miss dosages, you could foster medication safe strains of HIV, and your medicine might quit working.

A few different prescriptions and enhancements don't blend well in with HIV drugs, so ensure you educate your primary care physician concerning all that you're taking. This is another class of medication with only one prescription, fostemsavir (Rukobia). It is for grown-ups who have attempted numerous HIV prescriptions and whose HIV has been impervious to different treatments. It focuses on the glycoprotein 120 on the outer layer of the infection, preventing it from having the option to connect itself to the CD4 T-cells of your body's invulnerable framework. Maraviroc, or MVC (Selzentry), additionally stops HIV before it gets inside a sound cell, however in an unexpected way in comparison to combination inhibitors. It obstructs a particular sort of "snare" outwardly of specific cells so the infection can't connect.

This is another class of antiviral prescription explicitly for grown-ups living with HIV who have attempted various HIV meds and whose HIV has been impervious to different treatments. Ibalizumab-uiyk (Trogarzo) blocks your body's HIV contaminated cells from spreading the infection into those which are uninfected. It is given by IV. Since these "drug sponsors" can expand the degrees of different medications and hurt potential, you ought to consistently inform your primary care physician regarding the meds you are taking. The most ideal way to keep HIV side effects and inconveniences under control is to keep up with the specialist recommended timetable of antiviral drugs without missing any dosages. Assuming you do this, you'll help:

On the off chance that you don't feel good with your customary meds or you experience difficulty staying aware of portions, converse with your primary care physician. Together, you might have the option to change your medicine types and measurements to all the more likely location any indications or aftereffects. [1-5].

## Conflict of Interest

None.

## References

1. Halima, Dao, Lynne M Mofenson, Rene Ekpini and Matthew Barnhart, et al. "International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update." *J AIDS Clin Res* 197 (2007): S42-S55
2. Suzette, Glasner, Kevin Patrick, Michele Ybarra and Alexandra Venegas, et al. "Promising outcomes from a cognitive behavioral therapy text-messaging intervention targeting drug use, antiretroviral therapy adherence, and HIV risk behaviors among adults living with HIV and substance use disorders." *J AIDS Clin Res* 231 (2022): 109229
3. Matthew Page and Stephen Taylor. "Antiretroviral pharmacology and drug-drug interactions." *J AIDS Clin Res* 231 50 (2022): 220-227
4. Jennyl, versen, Salman ul Hasan Qureshi, Malika Zafar and Machteld Busz, et al. "Adherence to antiretroviral therapy among HIV positive men who inject drugs in Pakistan." *J AIDS Clin Res* 96 (2021): 103281
5. Sean, M Hughes, Claire N Levy, Fernanda L Calienes and Joanne D Stekler, et al. "Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection." *J AIDS Clin Res* 1 (2020): 100096

**How to cite this article:** Prema Menezes. "Antiretroviral Drugs Treatment for Prevention of HIV." *J AIDS Clin Res* 13 (2022): 870.

\*Address for Correspondence: Prema Menezes, Department of Medicine, University of North Carolina at Chapel Hill, USA, E-mail: prema\_menezes@med.unc.edu

**Copyright:** © 2022 Menezes P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Received** 04 January, 2022, Manuscript No. jar-22-52801; **Editor assigned:** 5 January, 2022, PreQC No. P-52801; **Reviewed:** 18 January, 2022, QC No. Q-52801; **Revised:** 19 January 2022, Manuscript No. R-52801; **Published:** 26 January, 2022, DOI: 10.37421/jar.2022.13.870